Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals — JPMorgan Healthcare Conference 2019

30 slides from Sunesis Pharmaceuticals's conference presentation, Jan 7, 2019

  1. Slide 1: JPMorgan Conference Update January 2019

    Slide 1: JPMorgan Conference Update January 2019

    JPMorgan Conference Update January 2019

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements, including statements related to the continued development of vecabrutinib (SNS-062) and other product candidates, including the timing and preliminary results of Phase 1b/2 trial of vecabrutinib and the therapeutic potentia

  3. Slide 3: Sunesis Overview: Kinase Inhibitor Pipeline

    Slide 3: Sunesis Overview: Kinase Inhibitor Pipeline

    Pre Clinical Phase 1 Phase 2 Phase 3 B-Cell Malignancies Vecabrutinib BTK Hematology/Solid Tumors SNS-510 PDK1 Sunesis Overview TAK-580 Pediatric Low-grade Glioma Key Milestones 2Q19: vecabrutinib clinical update at major medical conference 3Q19: vecabrutinib enters Phase 2 cohort expansion Kinase I

  4. Slide 4: Strong Growth Continues for BTK-Inhibitor Market

    Slide 4: Strong Growth Continues for BTK-Inhibitor Market

    Strong Growth Continues for BTK-Inhibitor Market Imbruvica: first covalent BTK inhibitor approved Imbruvica 2017sales: >$4B CLL market share leader (across all lines of therapy) EvaluatePharma estimates 2024 sales >$9B Company annual reports and earnings releases, EvaluatePharma World Preview Report

  5. Slide 5: Relapse From Ibrutinib Associated with Acquired Resistance Mutations

    Slide 5: Relapse From Ibrutinib Associated with Acquired Resistance Mutations

    Relapse From Ibrutinib Associated with Acquired Resistance Mutations Other Events 25%@ 4 years CLL Progression 19.1% @ 4 years Transformation 9.6% @ 4 years Woyach et al., J Clin Oncol 2017 Landmark Analysis of 308 Ibrutinib-Treated Patients 51% Discontinuation at 4 years Ibrutinib Acquired Resistan

  6. Slide 6: Understanding Prevalence of BTK Mutations

    Slide 6: Understanding Prevalence of BTK Mutations

    Understanding Prevalence of BTK Mutations ERIC (European Research Initiative on CLL) international, retrospective, observational, multicenter study To determine the prevalence of BTK and PLCg2 mutations in CLL patients relapsing or responding to ibrutinib in a real-world setting Presented at EHA 201

  7. Slide 7: Non-covalent BTK inhibitor

    Slide 7: Non-covalent BTK inhibitor

    Vecabrutinib Non-covalent BTK inhibitor

  8. Slide 8: BTK Kinase Domain Interaction Differentiated from Ibrutinib

    Slide 8: BTK Kinase Domain Interaction Differentiated from Ibrutinib

    Vecabrutinib BTK Kinase Domain Interaction Differentiated from Ibrutinib Cys481 vecabrutinib ibrutinib Hinge αC-helix Thr474 (gatekeeper) Activation loop Cys481 Hinge αC-helix Thr474 (gatekeeper) Activation loop Vecabrutinib distinct kinase domain interaction translates into improved selectivity ove

  9. Slide 9: Selective Kinase Inhibitor

    Slide 9: Selective Kinase Inhibitor

    Vecabrutinib - Selective Kinase Inhibitor Inhibits BTK with nanomolar potency Highly selective: IC50 < 100 nM in only 4 of 234 non-Tec family kinases1 Lack of EGFR inhibition: 1000-fold less potent than ibrutinib Emerging ITK role in CLL and other indications: Improves T cell number and function2 Co

  10. Slide 10: Differentiated Kinase Inhibition Profile

    Slide 10: Differentiated Kinase Inhibition Profile

    Vecabrutinib Differentiated Kinase Inhibition Profile TEC Family Kinases Inhibition of Other Kinases IC50 (nM) BTK ITK Tec# TXK* BMX* Notable Target Kinases Ibrutinib2 0.5 10.7 78 2.03 0.8 >10 more: EGFR family Acalabrutinib3 5.1 >1000 93 368 46 Selective Zanubrutinib4 0.22 30 1.9 n/a n/a N/A (not p

  11. Slide 11: Active in Wild-type and C481S Mutant BTK

    Slide 11: Active in Wild-type and C481S Mutant BTK

    Vecabrutinib Active in Wild-type and C481S Mutant BTK Activity of ibrutinib and acalabrutinib is profoundly affected1-4 Poor PK contributes to resistance in patients with BTK C481 mutations Vecabrutinib active against BTK C481S mutation and induces apoptosis in BTK-dependent lymphoma cell lines1-4 C

  12. Slide 12: Inhibition of ITK-Mediated Cellular Activities Comparable to Ibrutinib

    Slide 12: Inhibition of ITK-Mediated Cellular Activities Comparable to Ibrutinib

    Vecabrutinib Inhibition of ITK-Mediated Cellular Activities Comparable to Ibrutinib Inhibition of IL-2 Production Inhibition of PLCɣ1 Phosphorylation Sunesis data 1Tam et al., ASH 2015 VEC IC50 nM IBR IC50 nM ZAN1 IC50 nM 275 168 2536 VEC IC50 nM IBR IC50 nM ZAN1 IC50 nM 438 412 3433 IL-2 production

  13. Slide 13: Superior PK Profile Critical for Non-covalent BTK Inhibitor Activity

    Slide 13: Superior PK Profile Critical for Non-covalent BTK Inhibitor Activity

    Vecabrutinib Superior PK Profile Critical for Non-covalent BTK Inhibitor Activity 1 Neuman et al., ASH 2016 2 Adapted from Byrd et al., NEJM 2016 3 Adapted from Tam et al., ASH 2015 4 Adapted from Advani et al., J. Clin. Oncol. 2013 5 IMBRUVICA® (ibrutinib) prescribing information. Sunnyvale, CA: Ph

  14. Slide 14: Phase 1a: Profound and Sustained Target Inhibition

    Slide 14: Phase 1a: Profound and Sustained Target Inhibition

    Phase 1a: Profound and Sustained Target Inhibition Rapid, near complete inhibition of pBTK at all dose levels Prolonged inhibition seen at dose levels of ≥ 100 mg, supporting BID dosing Target dose level in patients likely 100-300 mg BID As concentrations increased, inhibition increased and variabil

  15. Slide 15: Phase 1b/2 Trial Status and Preliminary Data in B-Cell Malignancies

    Slide 15: Phase 1b/2 Trial Status and Preliminary Data in B-Cell Malignancies

    Vecabrutinib in B-Cell Malignancies Phase 1b/2 Trial Status and Preliminary Data

  16. Slide 16: Phase 1b/2 Study Design

    Slide 16: Phase 1b/2 Study Design

    Vecabrutinib in B-Cell Malignancies Phase 1b/2 Study Design Cohort 1 25 mg BID Cohort 2 50 mg BID Cohort 3 100 mg BID Cohort 4 200 mg BID RP2D Cohort Expansion Or continue escalation 300, 400, 500 mg BID CLL/SLL, MCL, WM, DLBCL-ABC, FL, MZL ≥ 2 prior regimens, includes BTK inhibitor if approved for

  17. Slide 17: Phase 1b/2 Study Status

    Slide 17: Phase 1b/2 Study Status

    Vecabrutinib in B-Cell Malignancies Phase 1b/2 Study Status Currently open in United States at 8 sites: 13 subjects treated to date 25 mg BID cohort: N=3 50 mg BID cohort: N=10 7 completed safety evaluation Safety profile supported dose escalation Cohort 3 (100 mg BID) open 3 subjects assigned slots

  18. Slide 18: Preliminary Data – ASH 2018 Baseline Characteristics

    Slide 18: Preliminary Data – ASH 2018 Baseline Characteristics

    Vecabrutinib Preliminary Data – ASH 2018 Baseline Characteristics All Subjects N=11a CLL Subjects N=7b Indication 7 CLL, 2 MCL, 2 WM Unmutated IGHV 5 (71%) Median age (range) years 66 (47-75) TP53 mutations /deletions 6 (86%) ECOG PS 0 3 (27%) BTK C481 Mutationsc 4 (57%) ECOG PS 1 8 (83%) Prior ther

  19. Slide 19: Preliminary Data – ASH 2018 Safety

    Slide 19: Preliminary Data – ASH 2018 Safety

    Vecabrutinib Preliminary Data – ASH 2018 Safety N=10 Adverse Event All Grades >15% N(%)a Grade ³ 3 N Related, Grade ³ 3 N Adverse Event All Grades >15% N(%) a Grade ³ 3 N Related, Grade ³ 3 N Anaemia 7 (70) 6 1 Constipation 2 (20) Neutropenia 5 (50) 5 1 Cough 2 (20) Night sweats 5 (50) Diarrhea 2 (2

  20. Slide 20: Vecabrutinib Steady-State Mean PK Profiles in B-Cell Malignancy Patients

    Slide 20: Vecabrutinib Steady-State Mean PK Profiles in B-Cell Malignancy Patients

    C2D1 C1D8 Generally dose proportional Sustained vecabrutinib exposure over dosing interval Vecabrutinib Steady-State Mean PK Profiles in B-Cell Malignancy Patients Consistent with Healthy Subjects Allan et. al. (ASH 2018 – Poster # 3141); Sunesis internal data

  21. Slide 21: Treatment Induced Rapid and Sustained Inhibition of BTK Phosphorylation

    Slide 21: Treatment Induced Rapid and Sustained Inhibition of BTK Phosphorylation

    Vecabrutinib Treatment Induced Rapid and Sustained Inhibition of BTK Phosphorylation Inhibition of pBTK for 5 subjects (4 CLL , 1 MCL) whose baseline C1D1 predose samples had adequate signal Postdose samples taken at 1 or 4 hours after dosing Allan et. al. (ASH 2018 – Poster # 3141); Sunesis interna

  22. Slide 22: Treatment Decreased Serum Cytokines in Subjects Who Completed Cycle 1

    Slide 22: Treatment Decreased Serum Cytokines in Subjects Who Completed Cycle 1

    Vecabrutinib Treatment Decreased Serum Cytokines in Subjects Who Completed Cycle 1 Consistent with inhibition of BTK signaling Baseline levels higher than previously reported in CLL (may indicate advanced disease) Median (range) pg/mL: CCL2 545.7 (11.8-2561.9), CCL3 320 (68.6-567), CCL4 1039 (22.5-3

  23. Slide 23: Summary: Preliminary Vecabrutinib Profile & Status

    Slide 23: Summary: Preliminary Vecabrutinib Profile & Status

    Summary: Preliminary Vecabrutinib Profile & Status Safety – appears well-tolerated in the context of advanced disease Pharmacokinetics – sustained exposure over dosing interval and generally dose proportional Pharmacodynamics – inhibition of BTK phosphorylation & cytokine reduction seen in patients

  24. Slide 24: Proprietary Pipeline SNS-510, PDK-1 inhibitor

    Slide 24: Proprietary Pipeline SNS-510, PDK-1 inhibitor

    Proprietary Pipeline SNS-510, PDK-1 inhibitor

  25. Slide 25: SNS-510 PDK1 Inhibitor: Exciting Preclinical Cancer Program

    Slide 25: SNS-510 PDK1 Inhibitor: Exciting Preclinical Cancer Program

    SNS-510 PDK1 Inhibitor: Exciting Preclinical Cancer Program Modality Small-molecule, oral inhibitor of PDK-1 Molecular Hypothesis Major mediator of PI3K signaling and activator of AKT PI3K-independent activator of RSK and S6K kinases Therapeutic Hypothesis Potentially broader activity than PI3K/AKT

  26. Slide 26: PDK1 Is the Major Mediator of PI3K Signaling

    Slide 26: PDK1 Is the Major Mediator of PI3K Signaling

    PDK1 Is the Major Mediator of PI3K Signaling Master kinase that activates kinases important to cell growth and survival in the AKT, PKC, RSK and SGK families Cunningham J T , and Ruggero D Cancer Discovery 2013;3:1099-1102

  27. Slide 27: Summary

    Slide 27: Summary

    Summary

  28. Slide 28: Financial Position and Capitalization

    Slide 28: Financial Position and Capitalization

    Financial Position and Capitalization 1 As of 9/30/18 2 As of 10/31/18; includes common (37.4M) and preferred as converted (6.3M) 3 As of 10/31/18 Ticker SNSS (NASDAQ) Cash & Equivalents $20.2 million1 Debt $7.5 million1 Shares 43.8 million2 Warrants Stock Options 0.2 million @ avg $3.723 3.4 millio

  29. Slide 29: Sunesis Highlights

    Slide 29: Sunesis Highlights

    Sunesis Highlights Large and rapidly growing market for BTK inhibitors Validated target, clear mechanism of action Covalent-BTK-inhibitor resistance is a growing problem Near-term milestones expected to create significant value Global rights retained for both BTK and PDK1 programs

  30. Slide 30: Thank You

    Slide 30: Thank You

    )) SUME SIS | Pharmaceuticals, In. Thank You

Source: SEC EDGAR · 8-K filed Jan 7, 2019

More decks from Sunesis Pharmaceuticals Inc